Catch up on what happened in optometry during the week of January 6-January 10.
Catch up with what Optometry Times shared this week:
By Jordana Joy, Associate Editor
Clinical stage biotech company Tenpoint Therapeutics announced positive topline results from BIO-II, a Phase 3 pivotal trial assessing BRIMOCHOL PF for the treatment of presbyopia. According to a company news release, the clinical trial successfully met pre-specified visual acuity primary endpoints in both the US and European Union (EU)/United Kingdom (UK) with statistically significant near vision improvements recorded at all time points over 8 hours (p<0.008). Those primary endpoints were agreed upon with the US FDA, European Medicines Agency, and the UK Medicines and Healthcare Products Regulatory Agency.1
By Laura M. Periman, MD
Dry eye disease (DED) continues to grow in prevalence and complexity, challenging eye care practitioners to adopt new tools and evolving treatment methods. As we head into 2025, practitioners should consider the bigger picture when it comes to understanding the causes of dry eye and embrace a multifaceted approach to treatment to achieve better patient outcomes.
By Khanh Hoang, OD
The collaboration between optometrists and ophthalmologists has evolved significantly over the past 4 decades, driven by advancements in technology, expanding scopes of practice, and a growing emphasis on patient-centered care. This article explores the dynamics of this relationship, highlighting the roles of both professions, the benefits of interdisciplinary collaboration, and the challenges that must be addressed to optimize patient outcomes.
By Cecelia Koetting, OD, FAAO, DipABO and Jordana Joy, Associate Editor
Optometry and ophthalmology tracks will continue to collide at this year's EnVision Summit, being held in Puerto Rico from February 14 to 17, 2025. Cecelia Koetting, OD, FAAO, Dipl ABO, cochair of EnVision Summit, remarks of previous success from the 2024 conference and what is getting her excited about this year's event. She cites comanagement, a focus on discussion-based panels, and the conference's family-friendly approach as features to look forward to this year.
By Jordana Joy, Associate Editor
Ophthalmic imaging and healthcare data solutions company Heidelberg Engineering has announced that its Epithelial Thickness Module, available through the ANTERION® Cornea app, has received US FDA clearance. The module provides eye care providers access to advanced, thickness mapping and data insights in order to evaluate epithelial and stromal structures.1 With detailed parameters and color maps, the module supports refractive surgery planning, ocular surface evaluation, and corneal ectasia assessment, among other cornea diagnostics, according to a news release.